Allena Pharmaceuticals, Inc. Operating Cash Flow

Operating Cash Flow of ALNA for past 10 years: annual, quarterly and twelve month trailing (TTM) including Operating Cash Flow growth rates and interactive chart. Operating cash flow (OCF) is a measure of the amount of cash generated by a company's normal business operations. Operating cash flow indicates whether a company can generate sufficient positive cash flow to maintain and grow its operations, otherwise it may require external financing for expansion or even survival. A negative number means the company is funded through external capital (debt or equity issuance) or cash available on the balance sheet. A positive number means that a company generates enough cash to pay for its operations.

Highlights and Quick Summary

  • Operating Cash Flow for the quarter ending March 31, 2022 was $-20 Million (a 57.42% increase compared to previous quarter)
  • Year-over-year quarterly Operating Cash Flow increased by 77.54%
  • Annual Operating Cash Flow for 2021 was $-45.4 Million (a 64.44% increase from previous year)
  • Annual Operating Cash Flow for 2020 was $-27.6 Million (a -35.98% decrease from previous year)
  • Annual Operating Cash Flow for 2019 was $-43.1 Million (a 35.37% increase from previous year)
  • Twelve month Operating Cash Flow ending March 31, 2022 was $-55.5 Million (a 22.2% increase compared to previous quarter)
  • Twelve month trailing Operating Cash Flow increased by 63.48% year-over-year
Trailing Operating Cash Flow for the last four month:
31 Mar '22 31 Dec '21 30 Sep '21 30 Jun '21
$-55.5 Million $-45.4 Million $-40.3 Million $-33.9 Million
Visit stockrow.com/ALNA for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Operating Cash Flow of Allena Pharmaceuticals, Inc.

Most recent Operating Cash Flowof ALNA including historical data for past 10 years.

Interactive Chart of Operating Cash Flow of Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals, Inc. Operating Cash Flow for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 $-20.04 – – – –
2021 $-12.73 $-11.4 $-11.29 $-9.96 $-45.38
2020 $-7.63 $-5.05 $-6.73 $-8.56 $-27.6
2019 $-11.93 $-9.07 $-12.83 $-9.81 $-43.1
2018 $-8.71 $-8.21 $-8.02 $-6.9 $-31.84
2017 $-6.84 $-3.52 $-4.41 $-6.3 $-21.07
2016 – – $-5.79 $-17.6 $-23.39
2015 $-13.17 – – – $-13.18

Business Profile of Allena Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.
© stockrow.com